Howard Capital Management Inc. Purchases 3,060 Shares of Amgen Inc. $AMGN

Howard Capital Management Inc. grew its position in shares of Amgen Inc. (NASDAQ:AMGN) by 17.1% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 20,976 shares of the medical research company’s stock after acquiring an additional 3,060 shares during the quarter. Howard Capital Management Inc.’s holdings in Amgen were worth $5,857,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Motley Fool Asset Management LLC lifted its position in shares of Amgen by 11.7% in the second quarter. Motley Fool Asset Management LLC now owns 27,913 shares of the medical research company’s stock worth $7,794,000 after purchasing an additional 2,924 shares in the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd acquired a new stake in Amgen in the 2nd quarter valued at $251,000. Fjarde AP Fonden Fourth Swedish National Pension Fund increased its stake in Amgen by 20.7% in the 2nd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 108,381 shares of the medical research company’s stock valued at $30,261,000 after buying an additional 18,600 shares during the last quarter. Advisory Alpha LLC lifted its position in Amgen by 16.0% during the 2nd quarter. Advisory Alpha LLC now owns 1,066 shares of the medical research company’s stock worth $298,000 after buying an additional 147 shares in the last quarter. Finally, SYM FINANCIAL Corp boosted its stake in shares of Amgen by 30.4% during the 2nd quarter. SYM FINANCIAL Corp now owns 2,729 shares of the medical research company’s stock worth $762,000 after buying an additional 636 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,267 shares of the stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total value of $376,286.33. Following the transaction, the senior vice president directly owned 7,209 shares of the company’s stock, valued at $2,141,000.91. This represents a 14.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.76% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. UBS Group decreased their price objective on Amgen from $326.00 to $317.00 and set a “neutral” rating for the company in a report on Wednesday, August 6th. Citigroup raised their price target on Amgen from $310.00 to $315.00 and gave the company a “neutral” rating in a research note on Wednesday, September 24th. Morgan Stanley boosted their price target on Amgen from $330.00 to $333.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 6th. Bank of America upped their price objective on Amgen from $261.00 to $272.00 and gave the stock an “underperform” rating in a research note on Friday, September 26th. Finally, Raymond James Financial assumed coverage on shares of Amgen in a research note on Wednesday, September 3rd. They issued a “market perform” rating for the company. Six investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $300.94.

Amgen Price Performance

NASDAQ:AMGN opened at $291.16 on Tuesday. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $335.88. The firm has a market capitalization of $156.75 billion, a price-to-earnings ratio of 23.81, a P/E/G ratio of 2.61 and a beta of 0.49. The stock’s 50 day moving average price is $287.89 and its two-hundred day moving average price is $287.33. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 7.24.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, topping analysts’ consensus estimates of $5.28 by $0.74. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The business had revenue of $9.18 billion for the quarter, compared to analyst estimates of $8.86 billion. During the same period in the previous year, the firm earned $4.97 EPS. The firm’s revenue was up 9.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. On average, analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 12th. Shareholders of record on Friday, August 22nd were issued a $2.38 dividend. This represents a $9.52 annualized dividend and a dividend yield of 3.3%. The ex-dividend date was Friday, August 22nd. Amgen’s payout ratio is currently 77.84%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.